Online Cognitive Training I-CAN to Improve Brain Function in Adults Receiving CAR-T Therapy for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

What this Trial Is About

Researchers are evaluating an online cognitive training program called Intervention to enhance Cognitive Augmentation and Neuroplasticity I-CAN in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma undergoing chimeric antigen receptor T-cell CAR-T therapy. The study aims to see if this training, delivered before and after CAR-T treatment, can help improve cognitive and neurological outcomes affected by cancer treatment side effects such as attention, memory, language, and executive function problems. Participants complete online I-CAN training sessions totaling about 20 hours over 8 weeks, with 2.5 hours per week before and after CAR-T therapy. The program focuses on improving brain function through speed and accuracy of processing, adaptability, generalizability, and engagement. Alongside training, blood samples are collected at various points during the study to explore molecular markers related to aging and cognition. Throughout the study, participants are assessed using cognitive tests like the Functional Assessment of Cancer Therapy-Cognition Perceived Cognitive Impairment FACT-Cog PCI and Montreal Cognitive Assessment MoCA, as well as measures of anxiety, depression, frailty, and healthcare use. Follow-up visits occur at 1, 3, and 12 months after CAR-T infusion to monitor adherence, satisfaction, cognitive changes, and other health outcomes over up to 14 months.

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma